• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Prostate-specific antigen (PSA) screening rates and factors associated with screening in Eastern Canadian men: Findings from cross-sectional survey data.加拿大东部男性的前列腺特异性抗原(PSA)筛查率及与筛查相关的因素:横断面调查数据的研究结果
Can Urol Assoc J. 2020 Jul;14(7):E319-E327. doi: 10.5489/cuaj.6072.
2
Changes in the uptake of screening for prostate cancer with prostate-specific antigen in Ontario between 2003 to 2012.2003年至2012年间安大略省前列腺特异性抗原前列腺癌筛查的接受情况变化。
Can Oncol Nurs J. 2020 Apr 1;30(2):125-132. doi: 10.5737/23688076302125132. eCollection 2020 Spring.
3
Lifetime and recent prostate specific antigen (PSA) screening of men for prostate cancer in Canada.加拿大男性前列腺癌的终生及近期前列腺特异性抗原(PSA)筛查情况。
Can J Public Health. 2006 May-Jun;97(3):171-6. doi: 10.1007/BF03405578.
4
5
Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Economic Analysis.基于前列腺特异性抗原(PSA)的前列腺癌人群筛查:一项经济学分析。
Ont Health Technol Assess Ser. 2015 May 1;15(11):1-37. eCollection 2015.
6
Disparities Associated with Shared Decision-making in Prostate Cancer Screening.前列腺癌筛查中与共同决策相关的差异。
Eur Urol Focus. 2023 Nov;9(6):1008-1015. doi: 10.1016/j.euf.2023.04.013. Epub 2023 May 15.
7
Associations of demographic and health-related characteristics with prostate cancer screening in Washington State.华盛顿州人口统计学及健康相关特征与前列腺癌筛查的关联
Cancer Epidemiol Biomarkers Prev. 1998 Jul;7(7):627-30.
8
Predictors of prostate cancer screening among health fair participants.健康博览会参与者中前列腺癌筛查的预测因素。
Public Health. 2005 Aug;119(8):686-93. doi: 10.1016/j.puhe.2004.08.021. Epub 2005 Jan 22.
9
Factors related to use of prostate cancer screening: the Alberta Tomorrow Project.与前列腺癌筛查使用相关的因素:艾伯塔省明日项目
Open Med. 2007 Apr 14;1(1):e3-e12.
10
Digital Rectal Examination Is Not a Useful Screening Test for Prostate Cancer.直肠指检对前列腺癌不是一种有用的筛查试验。
Eur Urol Oncol. 2023 Dec;6(6):566-573. doi: 10.1016/j.euo.2023.09.008. Epub 2023 Oct 6.

引用本文的文献

1
Determinants of Prostate Cancer Screening in Korean Men: A Nationwide Study Using the Korean National Cancer Screening Survey 2023.韩国男性前列腺癌筛查的决定因素:一项基于2023年韩国国家癌症筛查调查的全国性研究
Cancer Res Treat. 2025 Apr;57(2):539-546. doi: 10.4143/crt.2024.879. Epub 2024 Oct 29.
2
Factors affecting prostate cancer detection through asymptomatic prostate-specific antigen testing in primary care in England: evidence from the 2018 National Cancer Diagnosis Audit.影响英国基层医疗中通过无症状前列腺特异性抗原检测来发现前列腺癌的因素:来自2018年国家癌症诊断审计的证据
Br J Gen Pract. 2025 May 2;75(754):e300-e305. doi: 10.3399/BJGP.2024.0376. Print 2025 May.
3
Strategies used in managing conversations about prostate-specific antigen (PSA) testing among family physicians (FPs): a qualitative study.家庭医生在管理前列腺特异性抗原(PSA)检测相关对话时所采用的策略:一项定性研究。
BMJ Open. 2023 Apr 28;13(4):e073415. doi: 10.1136/bmjopen-2023-073415.
4
Socioeconomic Gradients in Prostate Cancer Incidence Among Canadian Males: A Trend Analysis From 1992 to 2010.社会经济地位与加拿大男性前列腺癌发病率的关系:1992 年至 2010 年的趋势分析。
Cancer Control. 2021 Jan-Dec;28:10732748211055272. doi: 10.1177/10732748211055272.
5
Incidence and Mortality of Prostate Cancer in Canada during 1992-2010.1992-2010 年加拿大前列腺癌的发病率和死亡率。
Curr Oncol. 2021 Feb 21;28(1):978-990. doi: 10.3390/curroncol28010096.

本文引用的文献

1
UPDATE - 2022 Canadian Urological Association recommendations on prostate cancer screening and early diagnosis Endorsement of the 2021 Cancer Care Ontario guidelines on prostate multiparametric magnetic resonance imaging.更新 - 2022年加拿大泌尿外科协会关于前列腺癌筛查和早期诊断的建议 认可2021年安大略癌症护理关于前列腺多参数磁共振成像的指南。
Can Urol Assoc J. 2022 Apr;16(4):E184-E196. doi: 10.5489/cuaj.7851.
2
Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force.基于前列腺特异性抗原的前列腺癌筛查:美国预防服务工作组的证据报告和系统评价。
JAMA. 2018 May 8;319(18):1914-1931. doi: 10.1001/jama.2018.3712.
3
Factors associated with prostate specific antigen testing in Australians: Analysis of the New South Wales 45 and Up Study.与澳大利亚男性进行前列腺特异性抗原检测相关的因素:新南威尔士州 45 岁及以上人群研究分析。
Sci Rep. 2018 Mar 9;8(1):4261. doi: 10.1038/s41598-018-22589-y.
4
State-by-state Variation in Prostate-specific Antigen Screening Trends Following the 2011 United States Preventive Services Task Force Panel Update.2011年美国预防服务工作组专家小组更新后前列腺特异性抗原筛查趋势的州际差异。
Urology. 2018 Feb;112:56-65. doi: 10.1016/j.urology.2017.08.055. Epub 2017 Oct 19.
5
Prostate-specific antigen testing in inner London general practices: are those at higher risk most likely to get tested?伦敦市中心普通诊所的前列腺特异性抗原检测:风险较高的人群是否最有可能接受检测?
BMJ Open. 2016 Jul 12;6(7):e011356. doi: 10.1136/bmjopen-2016-011356.
6
Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based Analysis.基于前列腺特异性抗原(PSA)的前列腺癌群体筛查:一项循证分析。
Ont Health Technol Assess Ser. 2015 May 1;15(10):1-64. eCollection 2015.
7
The influence of physician recommendation on prostate-specific antigen screening.医生建议对前列腺特异性抗原筛查的影响。
Urol Oncol. 2015 Oct;33(10):424.e1-7. doi: 10.1016/j.urolonc.2015.06.013. Epub 2015 Jul 21.
8
Prostate cancer.前列腺癌。
Lancet. 2016 Jan 2;387(10013):70-82. doi: 10.1016/S0140-6736(14)61947-4. Epub 2015 Jun 11.
9
Recommendations on screening for prostate cancer with the prostate-specific antigen test.关于使用前列腺特异性抗原检测进行前列腺癌筛查的建议。
CMAJ. 2014 Nov 4;186(16):1225-34. doi: 10.1503/cmaj.140703. Epub 2014 Oct 27.
10
Association of sociodemographic factors and prostate-specific antigen (PSA) testing.社会人口学因素与前列腺特异性抗原(PSA)检测的关联
Clin Biochem. 2014 Nov;47(16-17):164-9. doi: 10.1016/j.clinbiochem.2014.08.006. Epub 2014 Aug 14.

加拿大东部男性的前列腺特异性抗原(PSA)筛查率及与筛查相关的因素:横断面调查数据的研究结果

Prostate-specific antigen (PSA) screening rates and factors associated with screening in Eastern Canadian men: Findings from cross-sectional survey data.

作者信息

Tchir Devan, Farag Marwa, Szafron Michael

机构信息

University of Saskatchewan, School of Public Health, Saskatoon, SK, Canada.

SPADE, Doha Institute for Graduate Studies, Doha, Qatar.

出版信息

Can Urol Assoc J. 2020 Jul;14(7):E319-E327. doi: 10.5489/cuaj.6072.

DOI:10.5489/cuaj.6072
PMID:32017690
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7337718/
Abstract

INTRODUCTION

The prostate-specific antigen (PSA) test is used in Canada to detect prostate cancer (PCa) despite mixed recommendations. Complications arising from false-positives are common, posing as a cancer-screening concern. This work estimates some Canadian rates of PSA screening and identifies men at increased odds for PSA screening.

METHODS

The Canadian Community Health Survey (CCHS) from 2009/10 (Atlantic Canada; ATL), 2011/2012 (Ontario; ON), and 2013/2014 (Quebec; QC) were used. Lifetime and recent PSA screening with confidence intervals were constructed to estimate PSA screening in ATL, ON, and QC. Two logistic regression models (for men <50 and ≥50 years of age) were used to determine associations between factors and lifetime PSA screening.

RESULTS

PSA screening rates have increased in most age groups for ATL, ON, and QC since 2000/2001. Factors positively associated with lifetime PSA screening in men of all ages were: having a digital rectal exam, having a regular doctor, and having a colorectal exam. Fruit and vegetables consumption and non-smoking status were positively associated with lifetime PSA screening in men <50 years of age. High income and the presence of chronic health conditions were positively associated with lifetime PSA screening in men ≥50 years of age.

CONCLUSIONS

PSA screening rates have generally increased since 2000/2001 in Canada. Physician-related factors play a role in men at all ages, while different factors are associated in men <50 years of age and men ≥50 years of age. Limitations include the generalizability to all of Canada and the potential for recall bias.

摘要

引言

尽管存在不同的建议,但加拿大仍使用前列腺特异性抗原(PSA)检测来筛查前列腺癌(PCa)。假阳性结果引发的并发症很常见,这成为癌症筛查领域的一个问题。本研究估算了加拿大一些地区的PSA筛查率,并确定了PSA筛查几率增加的男性群体。

方法

使用了2009/10年(加拿大大西洋省份;ATL)、2011/2012年(安大略省;ON)和2013/2014年(魁北克省;QC)的加拿大社区健康调查(CCHS)数据。构建了有置信区间的终生和近期PSA筛查情况,以估算ATL、ON和QC地区的PSA筛查情况。使用两个逻辑回归模型(针对年龄<50岁和≥50岁的男性)来确定各因素与终生PSA筛查之间的关联。

结果

自2000/2001年以来,ATL、ON和QC地区大多数年龄组的PSA筛查率都有所上升。与各年龄段男性终生PSA筛查呈正相关的因素有:接受直肠指检、有固定的医生、接受结肠直肠癌检查。水果和蔬菜摄入量以及不吸烟状态与年龄<50岁男性的终生PSA筛查呈正相关。高收入和患有慢性健康状况与年龄≥50岁男性的终生PSA筛查呈正相关。

结论

自2000/2001年以来,加拿大的PSA筛查率总体呈上升趋势。与医生相关的因素在各年龄段男性中都发挥作用,而年龄<50岁和≥50岁的男性中存在不同的相关因素。局限性包括该结果对加拿大全国的普遍适用性以及存在回忆偏倚的可能性。